Product Name | Dovitinib |
Description |
FGFR3 inhibitor |
Purity | >98% |
CAS No. | 405169-16-6 |
Molecular Formula | C21H21FN6O |
Molecular Weight | 392.4 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Shipped Ambient |
Product Type | Inhibitor |
Solubility | Soluble in DMSO |
Source | Synthetic |
Appearance | Crystalline solid |
SMILES | CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N |
InChI | InChI=1S/C21H21FN6O/c1-27-7-9-28(10-8-27)12-5-6-14-16(11-12)25-20(24-14)18-19(23)17-13(22)3-2-4-15(17)26-21(18)29/h2-6,11,24-25H,7-10,23H2,1H3/b20-18- |
InChIKey | KCOYQXZDFIIGCY-ZZEZOPTASA-N |
Safety Phrases |
Classification: Skin Corrosion/Irritation, Category 2 Serious Eye Damage/Eye Irritation, Category 2 Target Organ Systemic Toxicity (single exposure), Category 3 Safety Phrases: S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. Hazard statements: H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. Precautionary statements: P302+352: IF ON SKIN: Wash with plenty of soap and water. P332+313: If skin irritation occurs, get medical advice/attention. P305+351+338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P337+313: If eye irritation persists, get medical advice/attention. P304+340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing. P312: Call a {POISON CENTER/doctor/...} if you feel unwell. |
Cite This Product | Dovitinib (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-500) |
Alternative Names | 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone |
Research Areas | Cell Signaling |
PubChem ID | 9886808 |
Scientific Background | Dovitinib is a potent growth factor receptor kinase inhibitor with effects against FLT-3, c-KIT, VEGFR, PDGFRß and CSF-1R. |
References | 1. Konecny G.E., et al. (2013) Mol. Cancer Ther. 12(5): 632–642. |
Reviews
There are no reviews yet.